The Chief Strategy Officer at Lucideon is set to help the emerging field of engineering biology translate from academia to pioneering use in industry.
Anike Te has been appointed honorary Aegis Professor of Engineering Biology at the University of Bristol's Faculties of Science and Life Sciences, for a three year term.
In the role, Anike will provide strategic direction and help the university identify when and how the academic stages of the new technology can be transferred to practical use in industry.
Anike said: "I am honoured and grateful to the University of Bristol for the appointment of Aegis Professor.
"It’s a great opportunity to bring together academia and industry in an innovative, collaborative approach.
"Lucideon is becoming increasingly involved in synthetic and engineering biology.
"It's a very exciting area of science, which touches on many industries and technologies, and creates solutions to real-world issues, both in the UK and internationally."
Anike joined Lucideon in 2018, with a brief to build upon the company’s continuing success in the aerospace, construction, energy, healthcare and technical ceramics sectors.
Based in Switzerland, she speaks five languages, practised as a dentist, and managed medical device clinical trials worldwide. She is a Certified Internal Auditor with experience in finance and internal controls.
Carmen Galan, Professor of Organic and Biological Chemistry and BrisEngBio Co-Lead for Innovation and Partnerships, said: "Working with Anike is a clear statement of our intention to work with industry to accelerate the translation of discovery synthetic biology research for real world benefit.
"The networks and expertise that Lucideon unlock for us aligns closely with our newest Bristol BioDesign Insititute research theme in Engineering Living and Sustainable Composite Interfaces."
As well as supporting Lucideon's operations in the UK and Europe, Anike is closely involved in the company's activities across the globe.
Lucideon has its headquarters in Staffordshire and a further facility in the UK at Cambridge Science Park. It also has offices in Switzerland, Austria and the Far East, alongside a strong presence in North America, with offices and laboratories in North Carolina, South Carolina, and New York.
Imre Berger, Professor of Biochemistry and BrisEngBio Co-Lead for Innovation and Partnerships added: "Anike's extensive expertise in establishing and leading international industrial networks will be a vital asset to accelerate new and potentially highly valuable projects that could evolve into transformative spin-outs and impacts.
"Having an external senior industrialist dedicate time to translation of research technologies is extremely valuable and Anike will be a perfect fit for this."